에 대한 최신 뉴스 AbbVie (NYSE:ABBV) 주식

AbbVie

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).

Biotech

Health Care

Technicals

Previews

Trading Ideas

General

ABBV

애브비(NYSE:ABBV)와 노바티스 AG(NYSE:NVS)가 금요일 시장 개장 전 4분기 실적을 발표할 준비를 하면서 투자자들은 두 제약 대기업 주가의 기술적 분석에 주목하고 있다. 애브비는 정체된 추세에 갇혀 있는 반면, 노바티스는 더 강한 상승 모멘텀을 보이고 있다.

애브비 vs 노바티스: 4분기 실적 발표 전 기술적 우위는 누구에게 있을까?

News

BIIB

LNTH

NGVT

NPSCY

RVNC

SAGE

SANW

SLRX

TMUS

대통령 조 바이든은 백악관에서의 마지막 며칠 동안 비폭력 마약 범죄자 석방를 우선시했지만, 틱톡? 이제는 대통령 당선자 도널드 트럼프의 문제이다. AP 통신에 따르면, 바이든은 금지 조치를 시행할 의사가 없으며, 이는 그의 마지막 정식 근무일인 1월 19일에 발효되고 트럼프의 취임식 하루 전이다.

딜 디스패치: 바이든이 틱톡 금지를 트럼프에게 넘기고, 또 다른 유명 소매업체 파산

Dividends

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

AMGN

시장이 불안정하고 혼란스러운 시기에는 많은 투자자들이 배당 수익률이 높은 주식으로 눈을 돌립니다. 이러한 주식은 높은 자유 현금 흐름을 가지고 있으며 주주들에게 높은 배당금을 지급하여 보상을 합니다.

Benzinga 독자들은 애널리스트 주식 등급 페이지를 방문하여 자신이 선호하는 주식에 대한 최신 애널리스트 의견을 검토할 수 있습니다. 트레이더들은 Benzinga의 방대한 애널리스트 등급

월가에서 가장 정확한 분석가들이 주목: 고배당 수익을 창출하는 3개의 헬스케어 주식

AbbVie Inc

Wells Fargo analyst Mohit Bansal maintains AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Overweight and raises the price target from $210 to $240.

Wells Fargo Maintains Overweight on AbbVie, Raises Price Target to $240

Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) in the last three months.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $213.08, a high estimate of $239.00, and a low estimate of $190.00. Marking an increase of 2.44%, the current average surpasses the previous average price target of $208.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1741125623_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive AbbVie. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$223.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$215.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$217.00</td>
<td>$211.00</td>
</tr>
<tr>
<td>Navin Jacob</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$190.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$210.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$239.00</td>
<td>$224.00</td>
</tr>
<tr>
<td>Gary Nachman</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$220.00</td>
<td>$218.00</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$214.00</td>
<td>$212.00</td>
</tr>
<tr>
<td>Evan David Seigerman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$215.00</td>
<td>$208.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$205.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$211.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$220.00</td>
<td>$212.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Neutral</td>
<td>$191.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to AbbVie. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of AbbVie compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for AbbVie's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into AbbVie's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ABBV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on AbbVie analyst ratings.</a>
<h2>About AbbVie</h2>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
<h3>Financial Milestones: AbbVie's Journey</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Positive Revenue Trend: Examining AbbVie's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 5.6% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -0.21%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): AbbVie's ROE excels beyond industry benchmarks, reaching -0.68%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): AbbVie's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.02%, the company may face hurdles in achieving optimal financial returns.
Debt Management: AbbVie's debt-to-equity ratio is notably higher than the industry average. With a ratio of 20.19, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

13 Analysts Have This To Say About AbbVie

B of A Securities analyst Tim Anderson maintains AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Neutral and raises the price target from $200 to $223.

B of A Securities Maintains Neutral on AbbVie, Raises Price Target to $223

AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) has outperformed the market over the past 5 years by 3.61% on an annualized basis producing an average annual return of 19.92%. Currently, AbbVie has a market capitalization of $374.56 billion. 
Buying $1000 In ABBV: If an investor had bought $1000 of ABBV stock 5 years ago, it would be worth $2,381.00 today based on a price of $212.17 for ABBV at the time of writing.
<h3>AbbVie's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741097708_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

AbbVie Announces SKYRIZI Available In Canada For Treatment Of Ulcerative Colitis Following Health Canada Approval

On Monday, AbbVie&nbsp;Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) and Gubra A/S announced a license agreement to develop GUB014295, a long-acting amylin analog for obesity. GUB014295 is currently in a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44069717/abbvie-and-gubra-announce-license-agreement-to-develop-an-amylin-analog-for-the-treatment-of-obesi" rel="noreferrer noopener">Phase 1 clinical trial</a>.
&#8220;Our partnership with Gubra marks our entry into the obesity field, offering a compelling opportunity based on the potential to address patient needs while also fostering long-term growth for our company,&#8221; said&nbsp;Robert Michael, CEO of AbbVie.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/01/43403416/is-big-pharma-about-to-win-goldman-sachs-weighs-in-on-340b-and-medicaid-shifts" rel="noreferrer noopener">Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts</a>
A potential long-acting amylin analog, GUB014295 is an agonist that specifically activates amylin and calcitonin receptors.
Amylin, a satiety hormone, has been identified as a potential therapeutic target for obesity, given its role in activating signals to the brain that result in appetite suppression and the reduction of food intake while also acting as an inhibitory signal to delay gastric emptying.&nbsp;
Under the terms of the agreement, AbbVie will lead the development and commercialization activities of GUB014295 globally.
Gubra will receive&nbsp;$350 million&nbsp;in total upfront payment and be eligible to receive up to&nbsp;$1.875 billion&nbsp;in development, commercial and sales milestone payments with tiered royalties on global net sales.
William Blair analyst Matt Phipps writes, &#8220;We believe this transaction highlights a growing interest in amylin agonists (and particularly dual amylin/calcitonin receptor agonists, or DACRAs) as a next wave of obesity assets, particularly for companies looking to break into the field despite being well behind GLP-1 leaders Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>).&#8221;
The analyst highlights a key question is whether AbbVie will develop GUB014295 as a standalone treatment, offering a milder weight loss option for those who cannot tolerate or do not respond to GLP-1/GIP agonists.
Alternatively, the company may combine it with GLP-1/GIP drugs like Novo Nordisk's CagriSema for greater weight loss. Investors are also interested in whether AbbVie plans to expand further in the obesity market through new business deals.
Price Action: ABBV stock is up 0.84% at $210.78 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44080418/trimble-and-stmicroelectronics-launch-precision-positioning-tech-for-iot-applications" target="_blank" rel="noreferrer noopener">Trimble, STMicroelectronics Launch Precision Positioning Tech For IoT Applications</a></li>
</ul>
Photo via Shutterstock.

Analyst Color

Large Cap

GUBRF

AbbVie Becomes Another Big Pharma To Enter Obesity Treatment Race

iShares Trust Dow Jones US Healthcare Sector Index Fund

CNBC Halftime Report Final Trades: Taiwan Semiconductor Manufacturing, AbbVie, Tradeweb Markets, iShares U.S. Healthcare ETF

Partnership marks AbbVie's entrance into the obesity field
Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global infrastructure for developing and commercializing therapies for patients in need
 Under the terms of the agreement, AbbVie will lead development and commercialization activities of GUB014295 globally. Gubra will receive $350 million in total upfront payment and will be eligible to receive up to $1.875 billion in development, commercial and sales milestone payments with tiered royalties on global net sales. The transaction closure is subject to regulatory approvals and other customary closing conditions.

AbbVie Enters Obesity Market with ~$2.2B Gubra Deal To Develop Next-Gen Amylin Therapy, With $350M Upfront Payment

<ul>
<li>The positive opinion is based on results from the pivotal Phase 3&nbsp;SELECT-GCA trial that evaluated the efficacy and safety of&nbsp;upadacitinib in adults with giant cell arteritis (GCA)1</li>
<li>The primary endpoint of sustained remission&#x2A; and key secondary endpoints, including reduction in disease flares, lower cumulative steroid exposure, and complete remission,† were met1&nbsp;&nbsp;</li>
<li>GCA&nbsp;is an autoimmune disease that causes inflammation of the large and medium cranial arteries, resulting in potentially debilitating symptoms2</li>
</ul>

AbbVie's RINVOQ Gains CHMP Backing For Giant Cell Arteritis, EU Decision Expected In H1 2025

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$42.00</td>
<td>$33.4K</td>
<td>6.5K</td>
<td>5.1K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/28/25</td>
<td>$27.00</td>
<td>$47.3K</td>
<td>322</td>
<td>2.3K</td>
</tr>
<tr>
<td>SWTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$65.00</td>
<td>$28.0K</td>
<td>11.9K</td>
<td>672</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$87.00</td>
<td>$30.2K</td>
<td>6</td>
<td>500</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$43.00</td>
<td>$41.2K</td>
<td>5.7K</td>
<td>81</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$230.00</td>
<td>$56.9K</td>
<td>1.9K</td>
<td>80</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/07/25</td>
<td>$915.00</td>
<td>$32.2K</td>
<td>177</td>
<td>66</td>
</tr>
<tr>
<td>BBIO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$30.00</td>
<td>$34.0K</td>
<td>6.0K</td>
<td>50</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$520.00</td>
<td>$58.0K</td>
<td>962</td>
<td>40</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$310.00</td>
<td>$53.0K</td>
<td>38</td>
<td>19</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a put option trade that happens to be bullish, expiring in 22 day(s) on March 21, 2025. This event was a transfer of 100 contract(s) at a $42.00 strike. The total cost received by the writing party (or parties) was $33.4K, with a price of $334.0 per contract. There were 6534 open contracts at this strike prior to today, and today 5139 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a put option sweep with bearish sentiment. It expires in 29 day(s) on March 28, 2025. Parties traded 720 contract(s) at a $27.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $47.3K, with a price of $65.0 per contract. There were 322 open contracts at this strike prior to today, and today 2378 contract(s) were bought and sold. 
• For SWTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>), we notice a call option sweep that happens to be bullish, expiring in 22 day(s) on March 21, 2025. This event was a transfer of 100 contract(s) at a $65.00 strike. This particular call needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $28.0K, with a price of $280.0 per contract. There were 11949 open contracts at this strike prior to today, and today 672 contract(s) were bought and sold. 
• For DXCM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), we notice a put option trade that happens to be bearish, expiring in 22 day(s) on March 21, 2025. This event was a transfer of 144 contract(s) at a $87.00 strike. The total cost received by the writing party (or parties) was $30.2K, with a price of $210.0 per contract. There were 6 open contracts at this strike prior to today, and today 500 contract(s) were bought and sold. 
• For BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we notice a call option trade that happens to be bullish, expiring in 323 day(s) on January 16, 2026. This event was a transfer of 25 contract(s) at a $43.00 strike. The total cost received by the writing party (or parties) was $41.2K, with a price of $1650.0 per contract. There were 5751 open contracts at this strike prior to today, and today 81 contract(s) were bought and sold. 
• Regarding ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we observe a call option sweep with bearish sentiment. It expires in 323 day(s) on January 16, 2026. Parties traded 67 contract(s) at a $230.00 strike. This particular call needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $56.9K, with a price of $850.0 per contract. There were 1944 open contracts at this strike prior to today, and today 80 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option trade with neutral sentiment. It expires in 8 day(s) on March 7, 2025. Parties traded 15 contract(s) at a $915.00 strike. The total cost received by the writing party (or parties) was $32.2K, with a price of $2150.0 per contract. There were 177 open contracts at this strike prior to today, and today 66 contract(s) were bought and sold. 
• Regarding BBIO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>), we observe a call option trade with bullish sentiment. It expires in 78 day(s) on May 16, 2025. Parties traded 50 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $34.0K, with a price of $680.0 per contract. There were 6077 open contracts at this strike prior to today, and today 50 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a put option trade with bearish sentiment. It expires in 113 day(s) on June 20, 2025. Parties traded 10 contract(s) at a $520.00 strike. The total cost received by the writing party (or parties) was $58.0K, with a price of $5800.0 per contract. There were 962 open contracts at this strike prior to today, and today 40 contract(s) were bought and sold. 
• For CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we notice a put option trade that happens to be bullish, expiring in 204 day(s) on September 19, 2025. This event was a transfer of 19 contract(s) at a $310.00 strike. The total cost received by the writing party (or parties) was $53.0K, with a price of $2790.0 per contract. There were 38 open contracts at this strike prior to today, and today 19 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

BBIO

DXCM

Hims & Hers Health, Inc. Class A Common Stock

HIMS

MRNA

SWTX

10 Health Care Stocks Whale Activity In Today's Session

AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) has outperformed the market over the past 10 years by 2.09% on an annualized basis producing an average annual return of 13.09%. Currently, AbbVie has a market capitalization of $360.27 billion. 
Buying $100 In ABBV: If an investor had bought $100 of ABBV stock 10 years ago, it would be worth $337.55 today based on a price of $204.08 for ABBV at the time of writing.
<h3>AbbVie's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740434411_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years

Former U.S. Secretary of Labor Robert Reich has called out the tax reduction plans of the Donald Trump-led administration in an X post, terming them as an &#8220;absolutely shameless giveaway,&#8221; that could shoot up the deficit by $4.6 trillion.
What Happened: The possible tax cuts for rich individuals and lower corporate tax rates are likely to widen the U.S. trade deficit, which the Trump 2.0 administration would most likely fund from the tariffs imposed on its trading partners.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Trump wants to extend his tax cuts for rich individuals, which would add $4.6T to the deficit. But he wants to go even further, cutting the corporate tax rate to 15%. It&#39;s yet another absolutely shameless giveaway. <a href="https://t.co/mkAWOFkkUd">pic.twitter.com/mkAWOFkkUd</a>
&mdash; Robert Reich (@RBReich) <a href="https://twitter.com/RBReich/status/1891623719304339516?ref_src=twsrc%5Etfw">February 17, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The data from the Center For American Progress Action Fund or CAPAF shows that cutting the corporate tax rate down to 15% would save all sectors and companies billions of dollars in tax.
<ul>
<li>Top 100 U.S. Companies: Can expect a total annual tax cut of $48 billion despite reporting $1.1 trillion in profits in their 2023 annual report.</li>
</ul>
<ul>
<li>Top 10 U.S. Companies: Reported more than $520 billion in profits according to their 2023 annual report can expect an annual tax cut of $23 billion. These include firms like Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Comcast Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>), and JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>).</li>
</ul>
<ul>
<li>Oil: The five largest U.S. oil companies, including Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>), Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>), Marathon Petroleum Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>), Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>), and Valero Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>) will receive an estimated $2.2 billion annual tax cut, despite over $80 billion in profits.</li>
</ul>
<ul>
<li>Pharma: The five largest U.S. drug makers, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), Merck &amp; Co Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) and Bristol-Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) will receive an estimated $3.1 billion annual tax cut, despite over $50 billion in profits.</li>
</ul>
<ul>
<li>Banking: The five largest Wall Street banks, JPMorgan Chase, Bank of America Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>), Citigroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>), Wells Fargo &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) and Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) will receive an estimated $4.1 billion annual tax cut, despite nearly $113 billion in profits.</li>
</ul>
<ul>
<li>Grocery: The five largest grocery companies, Kroger Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>), Costco Wholesale Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>), Albertsons Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>), Target Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) and Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) will receive an estimated $1.7 billion annual tax cut, despite over $29 billion in profits.</li>
</ul>
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43763438/trump-acting-like-a-mafia-don-says-this-economist-as-uncertainty-mounts-businesses-hold-back-in-fear-of-unforeseen-economic-shifts">Trump &#8216;Acting Like A Mafia Don,&#8217; Says This Economist As Uncertainty Mounts, Businesses Hold Back In Fear Of Unforeseen Economic Shifts</a>
Why It Matters: Trump has threatened all its trading partners with &#8220;reciprocal tariffs,&#8221; while already having implemented 25% on steel and aluminum imports.
According to economists like Craig Shapiro, who is a macro strategist at the Bear Traps Report, tariffs are the "<a href="https://www.benzinga.com/25/02/43587245/tariffs-are-the-only-way-to-fund-tax-cuts-without-deficit-expansion-argues-expert-as-it-takes-center-stage-in-donald-trumps-economic-plan">only way</a>" to fund tax cuts without expanding the federal deficit. 
Shapiro likened Trump&#8217;s governance to that of a &#8220;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43763438/trump-acting-like-a-mafia-don-says-this-economist-as-uncertainty-mounts-businesses-hold-back-in-fear-of-unforeseen-economic-shifts">Mafia Don</a>,&#8221; saying businesses are now uncertain about the economy&#8217;s direction. He noted fading &#8220;initial euphoria&#8221; and a &#8220;wait-and-see&#8221; approach from business leaders due to unclear policies, tariffs, trade agreement uncertainty, and fluctuating government spending. &#8211;
Price Action: On Friday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) which track the S&amp;P 500 and Nasdaq 100 indices, closed mixed. SPY fell 0.0049% to a value of $609.7, and QQQ was up by 0.42% to end at a value of $538.15, according to Benzinga Pro data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/02/43773441/ahead-of-gamestops-bitcoin-purchase-plans-blackrock-morgan-stanley-goldman-sachs-and-other-billion-dollar-funds-load-up-on-gme-stock-in-q4">Ahead Of GameStop&#8217;s Bitcoin Purchase Plans, BlackRock, Morgan Stanley, Goldman Sachs, And Other Billion Dollar Funds Load Up On GME Stock In Q4</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Government

Macro Notification

Economics

CMCSA

COST

Trump's Tax Cut Could Add $4.6 Trillion To Deficit, With $48 Billion Tax Relief For Top 100 Firms: Robert Reich

AbbVie's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) short percent of float has risen 3.88% since its last report. The company recently reported that it has 18.93 million shares sold short, which is 1.07% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.73 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>AbbVie Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739813412_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for AbbVie has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing AbbVie's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, AbbVie's peer group average for short interest as a percentage of float is 5.31%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About AbbVie?

Management

AbbVie Board Elected Robert A. Michael To Succeed Richard A. Gonzalez As Chairman

On Wednesday,&nbsp;AbbVie&nbsp;Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)&nbsp;and Xilio Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) announced a collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based immunotherapies, including masked T-cell engagers, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43654121/abbvie-and-xilio-therapeutics-announce-collaboration-and-option-agreement-to-develop-novel-tumor-a" rel="noreferrer noopener">leveraging Xilio&#8217;s proprietary technology</a>.
Xilio has developed a proprietary, clinically validated platform technology for tumor-activated biologics.
The company is advancing a pipeline of clinical and preclinical immunotherapies, including masked multispecific molecules, designed to achieve tumor-selective activation by leveraging masking and other unique components that are optimized for the specific target.
The action allows focused activity within the tumor microenvironment to minimize systemic adverse events.
Under the terms of the agreement, Xilio will receive $52.0 million in upfront payments, including a $10 million equity investment, and will be eligible to receive up to approximately $2.1 billion in contingent payments for option-related fees and milestones plus tiered royalties.
Concurrently, Xilio Therapeutics announced three wholly-owned preclinical programs for masked T cell engagers targeting prostate-specific membrane antigen for prostate cancer (PSMA), claudin 18.2 (CLDN18.2) and six-transmembrane epithelial <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43654150/xilio-therapeutics-announces-multiple-masked-t-cell-engager-programs" rel="noreferrer noopener">antigen of prostate 1 (STEAP1)</a>.
<ul>
<li>Xilio anticipates nominating a development candidate for its PSMA program in the ATACR format in the third quarter of 2025 and submitting an investigational new drug application (IND) in the first quarter of 2027.</li>
<li>CLDN18.2 has broad potential as a T cell engager target for gastric, pancreatic, esophageal, and lung cancers. Xilio anticipates nominating a development candidate for its CLDN18.2 program in the ATACR format in the fourth quarter of 2025 and submitting an IND in the second quarter of 2027.</li>
<li>STEAP1 has broad potential as a T cell engager target for prostate, colorectal, and lung cancers. Xilio anticipates nominating a development candidate for its STEAP1 program in the SEECR format in the first half of 2026 and submitting an IND in the second half of 2027.</li>
</ul>
Xilio anticipates that its existing cash and cash equivalents and the upfront payments under the agreement with AbbVie will be sufficient to fund its operating expenses and capital expenditure requirements into the first quarter of 2026.
Price Action: XLO stock is up 116.10% at $1.42 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43658118/martin-marietta-increases-revenue-expands-margins-ceo-expects-data-center-demand-to-offset-ongoing-softness" target="_blank" rel="noreferrer noopener">Martin Marietta Increases Revenue, Expands Margins: CEO Expects &#8216;Data Center Demand To Offset Ongoing Softness&#8217;</a></li>
</ul>

Contracts

Movers

Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday?

AbbVie And Xilio Therapeutics Announced A Collaboration And Option-to-license Agreement To Develop Novel Tumor-activated, Antibody-based Immunotherapies, As Per Which Xilio Will Receive $52.0M In Total Upfront Payments And Be Eligible To Receive Up To Around $2.1B In Total Contingent Payments For Option-related Fees And Milestones Plus Tiered Royalties

<ul>
<li>EMBLAVEOTM is the first and only monobactam/β-lactamase inhibitor combination antibiotic therapy approved by the U.S. FDA to treat complicated intra-abdominal infections, including those caused by Gram-negative bacteria</li>
<li>Gram-negative bacterial infections represent a significant public health threat due to their ability to develop resistance to antimicrobial therapies</li>
<li>Antimicrobial resistance (AMR) could lead to over 39 million deaths worldwide by 2050, and new treatments are urgently needed1</li>
</ul>
NORTH CHICAGO, Ill., Feb. 7, 2025 /PRNewswire/ -- AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) today announced that the U.S. Food and Drug Administration (FDA) has approved EMBLAVEO&#x2122;&nbsp;(aztreonam and avibactam), as the first and only fixed-dose, intravenous, monobactam/β-lactamase inhibitor combination antibiotic. It is approved in combination with metronidazole, for patients 18 years and older who have limited or no alternative options for the treatment of complicated intra-abdominal infections (cIAI), including those caused by the following susceptible Gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae complex, Citrobacter freundii complex, and Serratia marcescens. Approval of this indication is based on limited clinical safety and efficacy data for EMBLAVEO. Gram-negative bacterial infections are among the most challenging for healthcare professionals to control due to high antimicrobial resistance (AMR).2 When AMR develops, medicines intended to treat these infections become ineffective, increasing the risk of morbidity and mortality.2

U.S. FDA Approves EMBLAVEO For The Treatment Of Adults With Complicated Intra-Abdominal Infections With Limited Or No Treatment Options

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer recommended buying AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), saying it's &#8220;just a gem&#8221; and a &#8220;winner.&#8221; &nbsp;He added, &#8220;I can't believe the stock dropped so much.&#8221;
On Jan. 31, AbbVie reported fourth-quarter adjusted earnings per share of $2.16, beating the street view of $2.11. Quarterly sales of $15.102 billion, outpacing the analyst consensus estimate of $14.827 billion. Several analysts also raised their price targets on the stock following the earnings announcement.
<h3 class="wp-block-heading">Cramer Shares His Views On These Tech Stocks</h3>
MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) is a trade and not an investment, Cramer said. &#8220;You'd be catching it at the right time. I think the analysts are all starting to upgrade the, the enterprise software again. I think it's worth a stab, I really do.&#8221;
In the recent news, MongoDB has partnered with Lombard Odier to modernize core banking technology with generative AI.
The Mad Money host recommended pulling the trigger on Cerence Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNC#NASDAQ">CRNC</a>).
On the earnings front, Cerence is scheduled to announce its first quarter financial results on Thursday, Feb. 6.
<h3 class="wp-block-heading">Other Stocks In Focus</h3>
Cramer recommended buying Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) instead of going with Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>).
Supporting his view, Keefe, Bruyette &amp; Woods analyst Kyle Voigt, on Jan. 13, maintained Coinbase with a Market Perform and lowered the price target from $275 to $255.
Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) is the better one, Cramer said when asked about Tempus AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>). &#8220;If you want AI, then you go with Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>).&#8221;
Supporting that view, Loop Capital analyst Mark Schappel, on Jan. 14, maintained Tempus AI with a Buy and lowered the price target from $57 to $52.
Price Action:
<ul>
<li>MongoDB shares gained 2.7% to settle at $275.97 on Tuesday.</li>
<li>Tempus shares gained 0.5% to close at $61.85 during the session.</li>
<li>Coinbase shares fell 1.4% to settle at $280.39.</li>
<li>AbbVie shares fell 0.1% to close at $189.95 on Tuesday.</li>
<li>Cerence shares gained 6.2% to settle at $12.07.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43460681/jim-cramer-says-no-to-bigbear-ai-recommends-buying-this-tech-stock">Jim Cramer Says No To BigBear.ai, Recommends Buying This Tech Stock</a></li>
</ul>

Long Ideas

Media

$BTC

COIN

CRNC

Jim Cramer: This Health Care Stock Is A 'Winner,' Buy Bitcoin Instead Of Coinbase

Citigroup analyst Geoff Meacham maintains AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Buy and raises the price target from $205 to $215.

Citigroup Maintains Buy on AbbVie, Raises Price Target to $215

Investors with a lot of money to spend have taken a bearish stance on AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ABBV, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 24 uncommon options trades for AbbVie.
This isn't normal.
The overall sentiment of these big-money traders is split between 25% bullish and 50%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $105,465, and 21 are calls, for a total amount of $1,655,712.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $150.0 to $210.0 for AbbVie over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for AbbVie's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of AbbVie's whale trades within a strike price range from $150.0 to $210.0 in the last 30 days. 
<h3>AbbVie Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738607428_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$4.7</td>
<td>$4.55</td>
<td>$4.56</td>
<td>$195.00</td>
<td>$615.5K</td>
<td align="right">546</td>
<td>1.4K</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/07/25</td>
<td>$15.5</td>
<td>$14.2</td>
<td>$15.3</td>
<td>$175.00</td>
<td>$84.1K</td>
<td align="right">225</td>
<td>171</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/07/25</td>
<td>$16.1</td>
<td>$14.6</td>
<td>$15.15</td>
<td>$175.00</td>
<td>$83.3K</td>
<td align="right">225</td>
<td>61</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/07/25</td>
<td>$10.9</td>
<td>$10.1</td>
<td>$10.1</td>
<td>$180.00</td>
<td>$77.7K</td>
<td align="right">529</td>
<td>22</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/07/25</td>
<td>$16.85</td>
<td>$16.2</td>
<td>$16.58</td>
<td>$172.50</td>
<td>$72.9K</td>
<td align="right">200</td>
<td>45</td>
</tr>
</tbody>
</table>

<h3>About AbbVie</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Following our analysis of the options activities associated with AbbVie, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of AbbVie</h3>
<ul>
<li>Trading volume stands at 4,545,253, with ABBV's price up by 3.15%, positioned at $189.7.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 81 days.</li>
</ul>
<h3>What Analysts Are Saying About AbbVie</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $208.6.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Raymond James has revised its rating downward to Outperform, adjusting the price target to $220. 
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Neutral rating on AbbVie with a target price of $190. 
&#x2A; An analyst from Truist Securities has decided to maintain their Buy rating on AbbVie, which currently sits at a price target of $211. 
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on AbbVie, which currently sits at a price target of $205. 
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Buy rating on AbbVie with a target price of $217. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for AbbVie, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Looking At AbbVie's Recent Unusual Options Activity

Press Releases

AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

Allergan Aesthetics To Launch Three New State-of-the-Art Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training

AbbVie Declares Quarterly Dividend

AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors

AbbVie to Present at the TD Cowen's 45th Annual Health Care Conference

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis

AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity

AbbVie to Present at the Leerink Partners Global Healthcare Conference

SKYRIZI® (risankizumab) Now Available for Moderately to Severely Active Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Incyte

Insmed

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeOne Medicines

Vaxcyte

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Summit Therapeutics

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

Wells Fargo

B of A Securities

Citigroup

Truist Securities

Screenshot 2024-11-13 at 11.54.41 PM

TNXP

Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments

Screenshot 2024-05-14 at 6.27.53 PM

BRTX

CYNO

BioRestorative Therapies (NASDAQ: BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market

Screenshot 2024-02-24 at 12.03.42 AM

AXSM

New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain

애브비(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)와 노바티스 AG(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>)가 금요일 시장 개장 전 <a href="https://www.benzinga.com/earnings" target="_blank" rel="noopener">4분기 실적</a>을 발표할 준비를 하면서 투자자들은 두 제약 대기업 주가의 기술적 분석에 주목하고 있다.
애브비는 정체된 추세에 갇혀 있는 반면, 노바티스는 더 강한 상승 모멘텀을 보이고 있다.
차트를 분석해 보겠다.
또한 읽어보기: <a href="https://www.benzinga.com/general/health-care/25/01/43321236/rfk-jr-and-big-pharma-stocks-to-watch-as-health-secretary-hopeful-answers-pointed-questions-on-drugs-insurance-trump-exec-orders">RFK Jr.와 빅파마: 보건장관 후보가 약물, 보험, 트럼프 행정명령에 대한 날카로운 질문에 답변</a>
<h1 class="wp-block-heading">애브비: 중립 상태에 갇힘</h1>
애브비의 기술적 구성은 혼재된 신호를 나타다.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent013025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-758712" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30131850/Screenshot-2025-01-30-at-11.40.39-PM.png" sizes="(max-width: 626px) 100vw, 626px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30131850/Screenshot-2025-01-30-at-11.40.39-PM.png 626w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30131850/Screenshot-2025-01-30-at-11.40.39-PM-300x235.png 300w" alt="" width="626" height="490" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent013025&amp;t=be2bearmibe3na1">차트는 Benzinga Pro를 사용하여 생성되었습니다.</a>
애브비 주식은 단기 이동 평균선 위에서 거래되고 있으며, 8일 ($173.14) 및 20일 ($175.20) 단순 이동 평균(SMA)이 상승 신호를 보이고 있다. 그러나 장기 추세는 다른 이야기를 하고 있다. 애브비 주식은 50일 ($175.33) SMA와 밀접하게 정렬되어 있고 200일 ($178.77) SMA 아래에 있어 하방 압박이 지속되고 있음을 나타낸다. 이동 평균 수렴 발산(MACD) 지표가 -0.89로 음수를 나타내면서 이 약세 편향을 강화하고, 상대 강도 지수(RSI)가 50.39로 중립적 모멘텀을 시사한다.
전반적으로 애브비는 방향을 잡기 위해 고군분투하고 있으며, 약간의 매도 압박이 돌파 가능성을 억제하고 있다. 강력한 실적이 예상된다면 주가는 주요 저항선 수준을 넘어설 수 있지만, 현재 상황은 애브비가 추가적인 보합에 취약하다는 것을 시사한다.
<h1 class="wp-block-heading">노바티스: 상승 모멘텀을 타고 상승 중</h1>
반면, 노바티스는 확실히 상승하고 있다.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent013025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-758716" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30131921/Screenshot-2025-01-30-at-11.49.01-PM.png" sizes="(max-width: 626px) 100vw, 626px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30131921/Screenshot-2025-01-30-at-11.49.01-PM.png 626w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/30131921/Screenshot-2025-01-30-at-11.49.01-PM-300x235.png 300w" alt="" width="626" height="490" /></a></figure>
노바티스는 단기 및 중기 이동 평균선 위에서 거래되고 있으며, 8일 ($101.27), 20일 ($99.57) 및 50일 ($100.44) SMA가 모두 지지 역할을 하고 있다. MACD가 0.68로 상승 모멘텀을 나타내고, RSI가 63.61로 과매수 되지 않은 강세를 보여준다.
그러나 주가는 200일 SMA ($106.77) 아래에 있어 주의가 필요하다.
<h1 class="wp-block-heading">투자자에게 주는 시사점</h1>
실적 발표를 앞두고 노바티스는 기술적 우위를 보유하고 있으며, 더 강한 상승 구조와 상승 모멘텀을 보여준다. 반면 애브비는 범위에 갇혀 있으며 상승을 위한 촉매가 필요하다.
투자자들은 중요한 저항선 수준을 주의 깊게 지켜봐야 한다. 애브비는 $177 이상, 노바티스는 $106 이상에서 실적 발표 후 추가 움직임의 징후를 확인해야 한다.
다음 읽기: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43244657/goldman-sachs-raises-abbvies-price-forecast-sees-opportunity-despite-challenges">애브비, 면역학 성장으로 모멘텀 구축, 골드만 긍정적 유지</a></li>
</ul>
사진: Romix Image via Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

대통령 조 바이든은 백악관에서의 마지막 며칠 동안 <a href="https://www.benzinga.com/markets/cannabis/25/01/43054504/biden-commutes-sentences-of-nearly-2500-convicted-of-non-violent-drug-offenses-no-mention-of-cannabis-prisoners">비폭력 마약 범죄자 석방</a>를 우선시했지만, 틱톡? 이제는 대통령 당선자 도널드 트럼프의 문제이다.
<a href="https://apnews.com/article/tiktok-ban-trump-executive-order-1e95d9836bf6f8c0c245ed1c3234d968">AP 통신</a>에 따르면, 바이든은 금지 조치를 시행할 의사가 없으며, 이는 그의 마지막 정식 근무일인 1월 19일에 발효되고 <a href="https://www.benzinga.com/news/25/01/42995328/trump-inauguration-from-elon-musk-jeff-bezos-to-barack-obama-george-bush-and-bill-clinton-who-all-will-attend">트럼프의 취임식 하루 전</a>이다.
마감일이 다가오면서, 이 앱의 운명은 소위 &#8216;틱톡을 위한 국민 입찰&#8217;에 달려 있다. 이는 &#8220;샤크 탱크&#8221;의 케빈 오리어리(Kevin O&#8217;Leary)와 억만장자 프랭크 매코트(Frank McCourt)의 지원을 받는다. 분명히 틱톡의 미국 자산은 여전히 ​​손에 넣을 수 있지만 가격표나 거래가 <a href="https://www.benzinga.com/general/social-media/25/01/43060894/supreme-court-upholds-tiktok-ban-ahead-of-trumps-inauguration">며칠 안에</a> 현실적으로 완료될 수 있는지 여부에 대해서는 아직 언급이 없습니다.
<h2 class="wp-block-heading">파산 블록</h2>
조앤(Joann Inc.)은 12개월 이내에 두 번째 파산 계획을 수립하고 있다. 오하이오 기반의 이 패브릭 및 공예 소매업체는 약 800개 매점의 포트폴리오 구매자를 찾고 있다.
고든 브라더스 리테일 파트너스(Gordon Brothers Retail Partners)가 "스톡킹 호스(stalking horse)" 입찰자로 나타났지만, 조앤은 여전히 더 나은 제안을 기대하고 있다. 아마도 바늘귀를 통과시키는 법을 아는 사람에게서 말이다.
이전에 82세의 소매업체는 사모펀드 레너드 그린 앤 파트너스(Leonard Green &amp; Partners)의 관리 하에 있었으며, 2011년 16억 달러의 레버리지 인수로 인수되었다. 이 회사는 부채에 묶여 있었고 (<a href="https://wolfstreet.com/2024/03/18/brick-and-mortar-meltdown-fells-another-retailer-joann-inc-files-for-bankruptcy-3-years-after-ipo/">보도에 따르면</a> 2020년 10월 31일 기준 장기 부채가 9억 2,100만 달러였음) <a href="https://www.benzinga.com/news/21/03/20048728/ipo-preview-roblox-coupang-joann-lead-busy-week-of-offerings">2021년에 상장</a>되었다.
조앤은 <a href="https://apnews.com/article/joann-bankruptcy-chapter-11-filing-75093d4032907c59a45e472dd4e23229">2024년 3월</a>에 다시 비공개로 전환되었으며, 당시 10억 달러의 총 부채를 약 5억 달러 줄이는 데 성공했다.
지난해 자구 노력이 무색해진 조앤은 최근 소매업체들의 증가하는 피해 사례에 합류하고 있다: <a href="https://www.benzinga.com/news/legal/24/12/42710619/deal-dispatch-party-city-wraps-big-lots-goes-bust-container-store-continues">몇 가지를 예로 들면</a> 파티 시티(Party City), 빅랏츠(Big Lots), LL 플로링(LL Flooring), 더바디샵(The Body Shop) 및 더 컨테이너 스토어(The Container Store) 등이 있다.
컬크랜드 앤 앨리스(Kirkland &amp; Ellis)가 법률 문제를 처리하고 있으며, 센터뷰 파트너스(Centerview Partners LLC)가 재무 자문을 제공한다. 알바레즈 앤 마살 북미(Alvarez &amp; Marsal North America, LLC)가 구조조정 과정을 감독하고 있다.
<h2 class="wp-block-heading">신규 블록</h2>
<ul>
<li>투자 회사 KKR &amp; 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>)가 골드만삭스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>)를 고용하여 필리핀 핀테크 회사 마야(Maya)의 지분 매각 경매를 운영하도록 했다고 로이터가 보도했다.</li>
<li>뉴욕에 본사를 둔 KKR은 마야의 20% 이상의 지분을 보유하고 있으며, 매각이 진행된다면 마야의 가치는 20억 달러를 초과할 수 있다고 한 소식통이 전했다.</li>
<li>듀폰(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>)은 <a href="https://www.benzinga.com/news/large-cap/25/01/43028181/chemical-company-dupont-electronics-business-separation-retains-water-business">전자 사업 분리</a>를 추진하고 있다. 델라웨어 주 윌밍턴에 본사를 둔 이 회사는 거래가 11월 1일까지 완료될 것으로 예상하고 있다. 듀폰은 전략적 대안을 평가한 후 수자원 사업을 유지하기로 결정했다.</li>
<li>인제비티(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGVT#NYSE">NGVT</a>)는 성과 화학 산업 전문 분야를 매각하고 있으며, 사우스 캐롤라이나주 노스 찰스턴 부지의 일부를 매각할 계획다. 이 회사는 이익 현금 흐름을 개선하고 검토 과정을 연말까지 마무리할 것으로 기대하고 있다. 거래 여부는 <a href="https://www.benzinga.com/news/25/01/43027745/ingevity-explores-strategic-options-for-performance-chemicals-segment-to-strengthen-portfolio-projects-fy24-revenue-at-1-40-billion">아직 미정</a>이다.</li>
<li>S&amp;W 시드 컴퍼니(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANW#NASDAQ">SANW</a>)는 매물에 나와 있다. 이는 합병 또는 재자본화도 고려 중이며, 이는 더 큰 전략적 검토의 일환이다. 콜로라도주 롱몬트에 본사를 둔 이 회사는 호주 자회사를 이미 매각했다. 앨런 윌리츠(Alan Willits) 회장은 "우리는 주주 가치를 최적화하는 모든 이니셔티브를 지원하고 있으며, S&amp;W 시드가 향후 성공을 위해 최적의 위치에 있도록 보장하기 위해 잠재적 전략적 대안의 전체 범위를 고려할 것이다"라고 밝혔다.</li>
</ul>
참고: <a href="https://www.benzinga.com/25/01/43046722/starship-explodes-during-flight-test-elon-musk-says-success-is-uncertain-but-entertainment-is-guaranteed">스타 비행 시험 중 폭발, 일론 머스크: ‘성공은 불확실하지만 오락은 보장된다!'</a>
<h2 class="wp-block-heading">블록 업데이트</h2>
<ul>
<li>로렌코 곤칼베스(Lourenco Goncalves)는 월요일 기자 회견에서 주목을 받았다. <a href="https://www.bloomberg.com/news/articles/2025-01-14/cliffs-ceo-rips-evil-japan-and-doubles-down-on-america-first">블룸버그</a>에 따르면, 클리브랜드 클리프스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>)의 CEO는 일본을 "악당"이라고 부르며, 중국에 해로운 관행인 덤핑과 과잉 생산을 가르쳤다고 비난했다. 그의 발언은 클리브랜드 클리프스가 U.S. 스틸(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>)에 대한 새로운 입찰을 노리고 있는 가운데 나왔으며, 바이든이 일본제철(OTC:<a class="ticker" href="https://www.benzinga.com/stock/NPSCY#OTC">NPSCY</a>)의 <a href="https://www.benzinga.com/trading-ideas/movers/25/01/42787508/biden-blocks-14-9b-us-steel-takeover-shares-plunge">$140억 인수 시도</a>를 차단하기로 결정한 후이다. 자신의 회사를 잠재적 구매자로 포지셔닝하면서 곤칼베스의 수사는 철강 산업의 긴장을 고조시켰다. 일본제철은 이제 트럼프에게 <a href="https://www.benzinga.com/news/25/01/42994950/nippon-steel-eyes-trump-administration-to-revive-15b-us-steel-deal-blocked-by-biden-well-do-whatever-it-takes">거래 성사를 도와달라고 요청</a>하고 있다.</li>
<li>T-모바일(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>)은 비스타 미디어(Vistar Media)를 6억 달러에 인수할 것이다. 이 통신 회사는 이 거래가 광고 사업을 강화할 것으로 기대하고 있다고 로이터가 보도했다.</li>
</ul>
지난주 생명공학 및 제약 부문 거래가 잇따랐다. 다음은 벤징가의 보도 샘플이다:
<ul>
<li>바이오젠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>)은 세이지 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>)의 모든 미상환 주식을 <a href="https://www.benzinga.com/25/01/42957657/biogens-push-for-sage-therapeutics-could-strengthen-its-neurology-strategy-analysts-say">주당 7.22달러에 인수하겠다는</a> 비공식 제안을 제출했다. 골드만삭스 애널리스트인 살빈 리히터(Salveen Richter)는 이 제안이 출산 후 우울증(PPD) 치료제인 주르주배(Zurzuvae) 런칭의 재무적 성공을 고려할 때 전략적으로 타당하다고 믿고 있다.</li>
<li>GSK plc(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>)는 <a href="https://www.benzinga.com/25/01/42950025/gsk-to-buy-us-based-stomach-cancer-drug-developer-for-over-1-billion">IDRx, Inc., 위장관 간질성 종양(GIST)을 위한 정밀 치료제에 초점을 맞춘 생명공학 회사</a>를 10억 달러에 인수하기로 합의했다. 이 거래는 특정 규제 승인 이정표 후 GSK가 추가로 1억 5천만 달러를 지불해야 할 수도 있다.</li>
<li>일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)는 스콜피온 테라퓨틱스(Scorpion Therapeutics)의 초기 단계 <a href="https://www.benzinga.com/25/01/42949261/eli-lilly-scoops-up-scorpion-therapeutics-early-stage-cancer-program-for-25-billion">암 치료 프로그램을 25억 달러에 인수</a>했다.</li>
<li>브리스톨-마이어스 스퀴브(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)와 애브비(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)와 마찬가지로, 존슨앤드존슨(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)는 <a href="https://www.benzinga.com/general/biotech/25/01/42948170/like-bristol-myers-squibb-and-abbvie-johnson-johnson-seeks-to-bolster-neuropsychiatric-portfolio-with-15-billion-deal">150억 달러 거래로</a> 신경정신적 포트폴리오를 강화하려고 합니다.</li>
<li>크라운 래버러토리즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>)는 레반스 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>)의 모든 미상환 보통주를 주당 3.10달러에 인수하겠다고 제안했다.</li>
<li>셀러리어스 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>)는 디코이 테라퓨틱스(Decoy Therapeutics)와의 거래를 체결했다. 이 회사는 펩타이드 접합 치료제에 초점을 맞춘 초기 단계 생명공학 회사이다. 통합된 개체는 호흡기 질환과 위장관 종양학의 미충족 요구 사항을 목표로 할 것이다.</li>
<li>란테우스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>)는 <a href="https://www.benzinga.com/m-a/25/01/42937565/lantheus-strengthens-radiopharmaceutical-leadership-with-350m-acquisition-of-life-molecular-imaging">3억 5천만 달러에 라이프 몰레큘러 이미징을 인수하여</a> 방사선 치료제 분야에서의 입지를 강화했다.</li>
<li> </li>
</ul>
지난주 딜 디스패치의 에디션은 <a href="https://kr.benzinga.com/news/usa/stocks/%EB%94%9C-%EB%94%94%EC%8A%A4%ED%8C%A8%EC%B9%98-td-%EC%9D%80%ED%96%89%EC%9D%B4-%EC%B0%B0%EC%8A%A4-%EC%8A%88%EC%99%91-%EC%A7%80%EB%B6%84%EC%9D%84-%ED%8C%90%EB%A7%A4%ED%95%A0%EA%B9%8C-%EC%95%84/" target="_blank" rel="noopener">여기를 클릭하세요</a><a href="https://www.benzinga.com/ma/25/01/42921113/deal-dispatch-td-bank-charles-schwab-eyenovia-smart-share-hit-auction-block">.</a>
지금 읽기:
<ul>
<li><a href="https://www.benzinga.com/real-estate/25/01/43055513/eccentric-billionaire-howard-hughes-former-miami-estate-on-market-for-55-5-million">엑센트릭한 억만장자, 전설적인 영화 제작자 하워드 휴즈의 전 마이애미 저택이 5천 550만 달러에 매물로 나왔습니다.</a></li>
</ul>
이미지는 Shutterstock의 사진을 사용하여 생성되었습니다.


Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

시장이 불안정하고 혼란스러운 시기에는 많은 투자자들이 배당 수익률이 높은 주식으로 눈을 돌린다. 이러한 주식은 높은 잉여 현금 흐름을 가지고 있으며 주주들에게 높은 배당금을 지급하여 보상을 한다.
벤징가 독자들은 <a href="https://www.benzinga.com/analyst-stock-ratings">애널리스트 주식 등급</a> 페이지를 방문하여 자신이 선호하는 주식에 대한 최신 애널리스트 의견을 검토할 수 있다. 트레이더들은 벤징가의 방대한 애널리스트 등급 데이터베이스를 필터링하여 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">애널리스트 정확도</a>에 따라 정렬할 수 있다.
아래는 의료 부문에서 배당 수익률이 높은 세 개의 주식에 대한 가장 정확한 애널리스트들의 평가이다.
<h3 class="wp-block-heading">암젠 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)</h3>
<ul>
<li>배당 수익률: 3.67%</li>
<li>파이퍼 샌들러의애널리스트 데이비드 암셀렘(David Amsellem)은 1월 2일 주식에 대해 비중 확대 등급을 유지하고 목표 주가를 $344에서 $310으로 하향 조정했다. 이 애널리스트의 정확도는 66%이다.</li>
<li>BofA 증권의애널리스트 팀 앤더슨(Tim Anderson)은 12월 10일 주식에 대해 언더퍼폼 등급을 재부여하고 목표 주가를 $256로 설정했다. 이 애널리스트의 정확도는 63%이다.</li>
<li>최근 뉴스: 암젠은 12월 10일 1분기 배당금을 주당 $2.25에서 $2.38로 6% 인상했다.</li>
<li>Benzinga Pro의 실시간 뉴스 피드에서 <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1">최신 AMGN 뉴스를</a> 알림 받았다.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-716759" style="width: 619px; height: auto;" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044102/image-12.png" sizes="(max-width: 902px) 100vw, 902px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044102/image-12.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044102/image-12-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044102/image-12-768x705.png 768w" alt="" width="902" height="828" /></a></figure>
<h3 class="wp-block-heading">애브비 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</h3>
<ul>
<li>배당 수익률: 3.66%</li>
<li>BofA 증권의애널리스트 팀 앤더슨(Tim Anderson)은 12월 10일 주식에 대해 중립 등급을 재부여하고 목표 주가를 $191로 설정했다. 이 애널리스트의 정확도는 63%이다.</li>
<li>리링크 파트너스의 애널리스트 데이비드 라이징거(David Risinger)는 11월 22일 주식을 시장 평균에서 아웃퍼폼으로 상향 조정하고 목표 주가를 $206으로 설정했다. 이 애널리스트의 정확도는 75%이다.</li>
<li>최근 뉴스: 애브비는 12월 13일 님블 테라퓨틱스(Nimble Therapeutics)를 인수할 계획을 발표했다.</li>
<li>Benzinga Pro의 실시간 뉴스 피드에서 <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1">최신 ABBV 뉴스를</a> 알림 받았다.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-716760" style="width: 670px; height: auto;" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044151/image-13.png" sizes="(max-width: 917px) 100vw, 917px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044151/image-13.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044151/image-13-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044151/image-13-768x709.png 768w" alt="" width="917" height="847" /></a></figure>
<h3 class="wp-block-heading">CVS 헬스 코퍼레이션 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</h3>
<ul>
<li>배당 수익률: 6.02%</li>
<li>도이치 뱅크의 애널리스트 조지 힐(George Hill)은 12월 3일 주식을 보유에서 매수로 상향 조정하고 목표 주가를 $66으로 설정했다. 이 애널리스트의 정확도는 60%이다.</li>
<li>트루이스트 증권의 애널리스트 데이비드 맥도날드(David Macdonald)는 11월 20일 주식에 대해 매수 등급을 재확인하고 목표 주가를 $76에서 $67로 하향 조정했다. 이 애널리스트의 정확도는 63%이다.</li>
<li>최근 뉴스: 최근 법무부(DOJ)는 CVS가 2013년부터 불법 처방전으로 오피오이드 조합약과 과다량을 조제하여 관리 약물 법을 위반했다고 주장했다.</li>
<li>Benzinga Pro의 차트 도구가 <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1">CVS 주식의 추세</a>를 식별하는 데 도움을 주었다.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010325&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-716761" style="width: 584px; height: auto;" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044223/image-14.png" sizes="(max-width: 912px) 100vw, 912px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044223/image-14.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044223/image-14-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03044223/image-14-768x712.png 768w" alt="" width="912" height="845" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio">
<div class="wp-block-embed__wrapper"><iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&amp;feature=oembed" width="500" height="281" frameborder="0" allowfullscreen="allowfullscreen"></iframe></div>
</figure>
더 읽기:
<ul>
<li><a href="https://www.benzinga.com/25/01/42763645/how-to-earn-500-a-month-from-acuity-brands-stock-ahead-of-q1-earnings">애큐티 브랜드 주식으로 월 $500를 버는 방법</a></li>
</ul>
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

슈왑 미국 배당주 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHD#NYSE">SCHD</a>)는 12월에 7% 이상 하락하면서 지난 한 달 동안 1년간 상승폭의 절반 이상을 반납했다. <a href="https://www.benzinga.com/24/12/42528079/this-high-yield-dividend-etf-is-undergoing-a-harsh-reversal-signaling-bearish-trends-here-what-you-need-to-know" target="_blank" rel="noopener">SCHD 펀드가 하락한 이유를 살펴보자.</a>
알아야 할 내용: 슈왑 미국 배당주 ETF는 4개의 제약주가 펀드 전체 보유 자산의 15.83%를 차지해 헬스케어 부문에 큰 비중을 두고 있다. 헬스케어 섹터는 최근 도널드 트럼프 대통령 당선인의 행정부 책임자 임명 및 <a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction" target="_blank" rel="noopener">정책 변화</a>에 대한 불확실성이 높아지면서 실적이 저조했다.
<h2>헬스케어 부문 보유 종목</h2>
브리스톨 마이어스 스퀴브(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)는 펀드 내에서 가장 큰 제약 보유 종목으로, 자산의 4.64%를 차지한다. 지난 한달 동안 주가는 2.6% 하락했다.
화이자(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)도 펀드의 상위 10개 보유 종목에 속흔다. 백신 제조사 화이자는 앞으로 불확실한 정치 및 규제 환경에 직면하면서 대선 이후 5% 이상 하락했다.
애브비(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)와 암젠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)도 헬스케어 보유 종목이다. 애브비 주가는 소폭 하락했지만 암젠 주가는 12월에 체중 감량 약물 후보인 마리타이드(MariTide)의 실망스러운 <a href="https://www.benzinga.com/content/42377651/amgen-stock-falls-on-weight-loss-drug-data-overreaction-or-fair" target="_blank" rel="noopener">임상시험 </a>결과로 인해 10% 이상 하락했다.
금리: 슈왑 미국 배당주 ETF에 영향을 미칠 수 있는 또 다른 요인은 불확실한 금리 환경이다. 저금리 환경에서는 배당금이 투자자에게 더 매력적으로 다가오는 경향이 있다. 최근 연준의 발언에 따르면 인플레이션이 연준의 목표 금리인 2%를 상회하는 등 매파적인 전망이 나온다.
또한 트럼프가 해외 수입품에 대한 관세를 인상하겠다고 공약한 만큼 차기 트럼프 행정부가 인플레이션을 재점화하고 금리를 더 오래 유지할 수 있는 요인으로 작용할 수 있다.
금리가 높으면 채권 및 기타 채권형 증권의 수익률 경쟁이 치열해져 배당 수익률은 상대적으로 매력도가 떨어지게 된다.
이미지: Shutterstock
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%EC%97%94%EB%B9%84%EB%94%94%EC%95%84-%EC%A3%BC%EA%B0%80-4-%EA%B0%80%EA%B9%8C%EC%9D%B4-%EC%83%81%EC%8A%B9%ED%95%9C-%EC%9D%B4%EC%9C%A0%EB%8A%94/" target="_blank" rel="noopener">엔비디아, 주가 4% 가까이 상승한 이유는?</a>
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Specialty ETFs

Politics

ETFs

SCHD

슈왑 미국 배당주 ETF(SCHD), 12월에 7% 이상 하락한 이유는?

JP모건에 따르면 미국 대형 바이오제약주는 2년 연속 전체 시장 대비 저조한 실적을 기록했으며, 2025년에 대한 투자자들의 전망은 혼조세를 보이고 있다.
강력한 펀더멘털과 신약 파이프라인의 발전에도 불구하고 정치적 불확실성과 섹터 순환과 같은 요인으로 인해 S&amp;P 500 대비 바이오제약 섹터의 성과가 저조했다.
2024년 바이오제약 주식은 9.6% 상승하여 S&amp;P 500의 28.5% 상승률에 미치지 못했다. 그러나 JP모건 애널리스트들은 몇몇 주요 기업에 대해 긍정적인 전망을 유지하고 있다.
JP모건에서 가장 많이 추천하는 일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)는 당뇨병 및 비만 치료제인 <a href="https://www.benzinga.com/general/biotech/24/10/41622207/eli-lilly-q3-earnings-mounjaro-sales-more-than-double-takes-2-98-billion-hit-to-profit-cuts-annua">마운자로(Mounjaro)와 젭바운드(Zepbound)</a>에서 지속적인 성장을 보일 것으로 예상된다. 또한 JP모건은 일라이 릴리의 강력한 파이프라인을 강조하면서 2030년대까지 두 자릿수 매출과 수익 성장을 예측했다.
브리스톨-마이어스 스퀴브(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)는 최고 매출 100억 달러를 달성할 수 있는 조현병 치료제인 코벤피(Cobenfy)의 강력한 잠재력으로 JP모건의 &#8216;포커스 리스트&#8217;에 추가되었다.
마찬가지로 머크(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)와 리제네론 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40168774/mercks-blockbuster-vaccine-gardasil-sales-in-china-analyst-highlights-challenges-an">주요 제품에 영향을 미치는</a> <a href="https://www.benzinga.com/general/biotech/24/04/38208816/eye-drug-eylea-price-manipulation-regeneron-faces-us-justice-department-allegations-over-medicare">경쟁 압력</a> 및 지역 역학과 관련된 2024년의 어려움에 이어 2025년에는 회복될 것이르오 예상된다.
길리어드 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)는 <a href="https://www.benzinga.com/quote/GILD">HIV 예방을 위한</a> 레나카파비르(lenacapavir)의 2025년 중반 출시가 예상됨에 따라 성장할 것으로 예상된다.
또한 애브비(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)는 단기적인 <a href="https://www.benzinga.com/quote/ABBV">파이프라인 개발</a>이 적음에도 불구하고 스카이리지(Skyrizi)와 린보크(Rinvoq) 판매 호조에 힘입어 밸류에이션이 매력적이라고 보았다.
한편, 동물 건강 관련 주식도 2025년에 반등할 것으로 예상한다. JP 모건은 조에티스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>)를 이 분야에서 가장 강력한 선택지로 보고 있으며, 고배당 매출 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41722660/zoetis-q3-earnings-beat-companion-animal-segment-growth-gives-confidence-into-2025-" target="_blank" rel="noreferrer noopener">성장과 마진 확장</a>의 잠재력을 언급했다. 아이덱스 래버러토리스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>)는 또 다른 다른 확실한 선택이며, 성과는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41659873/idexx-laboratories-adjusts-guidance-as-q3-revenue-growth-slows-analyst-notes-fewer-" target="_blank" rel="noreferrer noopener">수의사 방문 수 회복</a>에 달려 있다. 한편 엘랑코 애니멀 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>)는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41817807/elanco-animal-q3-earnings-profit-beat-new-products-and-stabilized-business-to-drive" target="_blank" rel="noreferrer noopener">신제품 출시</a>와 관련된 불확실성에 직면해 있다.
그리고 특수 의약품 부문은 2024년에 가격 안정성과 공급 역학 개선의 혜택을 받아 조기에 안정화 조짐을 보였다. 페리고(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRGO#NYSE">PRGO</a>)와 비아트리스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>)는 유망한 기회로 강조되었으며 테바 파마슈티컬(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>)는 올해 강력한 임상 시험 <a href="https://www.benzinga.com/general/biotech/24/12/42561832/teva-pharmaceutical-releases-impressive-phase-2-candidate-data-for-gastro-related-diseases" target="_blank" rel="noreferrer noopener">결과를 발표했지만</a> 성장 문제에 직면할 수 있다.
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%ED%80%80%ED%85%80-%EC%BB%B4%ED%93%A8%ED%8C%85-%EB%B8%94%EB%9E%99%EB%B2%A0%EB%A6%AC-%EB%A3%A8%EC%8B%9C%EB%93%9C-%EB%93%B1-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EB%8C%80-%EC%83%81%EC%8A%B9%ED%95%9C/">퀀텀 컴퓨팅, 블랙베리, 루시드 등 지난주 최대 상승한 중형주 (12월 16일~20일)</a>
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

ELAN

GILD

IDXX

PRGO

REGN

TEVA

VTRS

일라이 릴리, 머크 등 대형 바이오제약사 2025년 전망: JP모건

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 모놀리식 파워 시스템즈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>)의 주식은 24.68% 하락했다. 이는 엣지워터 리서치(Edgewater Research)의 분석 보고서에 따라 모놀리식의 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) 블랙웰(Blackwell) GPU에 대한 할당이 전력 관리 IC의 성능 문제로 위험에 처해 있다고 밝힌 후 발생한 일이다.
2. 슈퍼 마이크로 컴퓨터(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)의 주식은 24.23% 하락했다. 이는 회사가 최근  <a href="https://www.benzinga.com//node/41938588" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">2024년 9월 30일 종료 분기 보고서를 제때</a> 제출할 수 없다고 발표한 후 주가가 급락했다.
3. 모더나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)의 주식은 21.31% 하락했다. 이는 도널드 트럼프 대통령 당선인이 로버트 F. 케네디 주니어를 보건복지부(HHS) 장관으로 지명한 후 <a href="https://www.benzinga.com//node/42013119" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">백신 주식에 대한 압박</a>이 발생했기 때문이다.
4. 레이도스 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>)의 주식은 19.04% 하락했다. 이는 트럼프 대통령 당선인이 인수 기간 동안 연방 정부 주요직 임명을 했기 때문으로, 투자자들은 &#8220;<a href="https://www.benzinga.com//node/42013424" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">정부 효율성 부서</a>&#8220;에서의 가능한 삭감의 영향을 평가할 수 있다.
5. 먼데이닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>)의 주식은 회사가 3분기 실적이 예상치를 웃돌고 연간 전망을 상향 조정했음에도 <a href="https://www.benzinga.com//node/41877454" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">불구하고</a> 지난주 18.94% 하락했다.
6. 백스사이트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCVX#NASDAQ">PCVX</a>)의 주식은 18.60% 하락했다. 이는 도널드 트럼프 대통령 당선인이 로버트 F. 케네디 주니어를 HHS 장관으로 지명한 후 백신 주식에 대한 압박이 발생했기 때문이다.
7. 부즈 앨런 해밀턴 홀딩(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>)의 주식은 18.59% 하락했다.
8. 애브비(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)의 주식은 17.30% 하락했다. 이는 2상 EMPOWER 시험이 <a href="https://www.benzinga.com/general/biotech/24/11/41881546/abbvie-9billion-schizophrenia-studies-bristol-myers-stock-surges" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">주요 목표</a>를 달성하지 못했다고 발표한 후 발생한 일이다.
9. CACI 인터내셔널(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CACI#NYSE">CACI</a>)의 주식은 17.16% 하락했다.
10. 샤오펑(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>)의 주식은 16.89% 하락했다. 이는 미국에 상장된 중국 주식의 광범위한 하락세를 반영한 것이다. 이러한 시장 변화는 트럼프 당선인의 행정부 인사를 둘러싼 우려의 영향을 받을 수 있으며, 이는 <a href="https://www.benzinga.com//node/41946780" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">중국에 대한 더욱 강경한 입장</a>을 나타낼 수 있다.
또한 읽어보세요:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%87%BC%ED%94%BC%ED%8C%8C%EC%9D%B4-%EB%94%94%EC%A6%88%EB%8B%88-%EB%B0%8F-%EC%BD%94%EC%9D%B8%EB%B2%A0%EC%9D%B4%EC%8A%A4%EB%8A%94-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC/" target="_blank" rel="noopener">쇼피파이, 디즈니 및 코인베이스는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (11월 11일-15일)</a></li>
</ul>
이미지 출처: Robert Way via Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

CACI

LDOS

MNDY

MPWR

NVDA

PCVX

SMCI

XPEV

슈퍼 마이크로, 모더나 및 샤오펑은 지난주 최악의 성과를 보인 10개 대형주 중 일부 (11월 11일-15일)

바이킹 펀드 매니지먼트(Viking Fund Management)의 최근 13F 공시를 보면, 2024년 대선을 앞두고 일부 석유 기업 주식을 매도하는 등 3분기에 어떤 회사를 사고 팔았는지 확인할 수 있다. 13F 공시를 통해 보고한 포지션은 다음과 같다.
우선, 바이킹펀드매니지먼트는 3분기에 일부 대형 석유 회사의 포지션을 포함하여 8개 종목을 완전히 매각했다.
<h3>3분기 매도 종목:</h3>
&#8211; 마라톤 오일 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRO#NYSE">MRO</a>) 
&#8211; 쉘 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHEL#NYSE">SHEL</a>) 
&#8211; SM 에너지 컴퍼니 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SM#NYSE">SM</a>) 
&#8211; 서던 코퍼 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCCO#NYSE">SCCO</a>) 
&#8211; 소시에다드 퀴미카 미네라 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQM#NYSE">SQM</a>) 
&#8211; 머피 USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUSA#NYSE">MUSA</a>) 
&#8211; 사노피 SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NYSE">SNY</a>) 
&#8211; 캑터스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHD#NYSE">WHD</a>)
다음은 3분기에 펀드에 추가된 신규 주식이다. 분기 말 기준으로 달러 가치에 따라 크기별로 정렬되었다.
<h3>3분기 신규 매수 종목:</h3>
&#8211; 코디악 가스 서비스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGS#NYSE">KGS</a>) 
&#8211; EQT 코퍼레이션 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) 
&#8211; HF 싱클레어 코퍼레이션 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DINO#NYSE">DINO</a>) 
&#8211; 웨더포드 인터네셔널 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WFRD#NASDAQ">WFRD</a>) 
&#8211; NRG 에너지 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) 
&#8211; 버티브 홀딩스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) 
&#8211; 차트 인더스트리즈 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NYSE">GTLS</a>) 
&#8211; 비스타 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) 
&#8211; 유나이티드 마이크로엘릭트로닉스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UMC#NYSE">UMC</a>) 
&#8211; 에버소스 에너지 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ES#NYSE">ES</a>) 
&#8211; 포트랜드 제너럴 일렉트릭 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POR#NYSE">POR</a>) 
&#8211; 레스토랑 브랜즈 인터내셔널 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QSR#NYSE">QSR</a>) 
&#8211; 뉴트리엔 (NTR.TO – Canada)
주요 변화: 바이킹펀드는 기존 포지션에 대한 여러 가지 변화를 보였고, 새로운 포지션을 개시하기도 했다.
다음은 분기 중 기존 보유 주식 중 추가 매수 규모가 가장 큰 종목이다.
&#8211; 키비타스 리소시스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIVI#NYSE">CIVI</a>): +16,900% 
&#8211; 브로드컴 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>): +882% 
&#8211; 라이온델바젤 인더스트리즈 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>): +400% 
&#8211; 리오 틴토 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIO#NYSE">RIO</a>): +386% 
&#8211; 다우 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>): +200%
다음은 분기 중 기존 보유 주식 중 매도 규모가 가장 큰 종목이다.
&#8211; 텍사스 퍼시픽 랜드 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPL#NYSE">TPL</a>): -60% 
&#8211; 테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>): -50% 
&#8211; 할리버튼 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>): -40% 
&#8211; 엑슨모빌 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>): -36% 
&#8211; 오빈티브 (OVV.TO – Canada): -33%
왜 중요한가: 다음은 분기 말 기준으로 바이킹펀드에서 가장 큰 포지션을 달러 가치와 펀드에서 차지하는 비율로 순위를 매긴 것이다.
&#8211; 브로드컴: 2,796만 달러, 4.5% 
&#8211; 애브비 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>): 2,488만 달러, 4.0% 
&#8211; 넥스테라 에너지 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>): 2,265만 달러, 3.7% 
&#8211; 엔터지 코퍼레이션 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETR#NYSE">ETR</a>): 1,627만 달러, 2.6% 
&#8211; 블랙록(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>): 1,424만 달러, 2.3%
바이킹펀드는 브로드컴에 대한 포지션을 크게 늘렸으며, 여전히 가장 큰 보유 종목이다. 또한 분기 동안 여러 석유주가 매각되었지만, 에너지 관련 새로운 포지션들이 열리기도 했다.
사진 출처: Shutterstock
이 기사도 읽어보세요: <a href="_wp_link_placeholder" data-wplink-edit="true">13F 공시: 넬슨 펠츠가 이끄는 트리안펀드매니지먼트의 대선 전 포트폴리오 리밸런싱</a>
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

AVGO

CIVI

DINO

GTLS

MUSA

SCCO

SHEL

TSLA

WFRD

바이킹 펀드: 3분기에 대형 석유주 매각, 테슬라 포지션 절반으로 축소, 브로드컴 추가 매입

S&amp;P 500 기업들 중 약 <a href="https://www.benzinga.com/news/earnings/24/07/39769910/goldman-sachs-q2-earnings-revenue-and-eps-beat-investment-banking-fees-up-21-hikes-dividend" target="_blank" rel="noopener" data-google-interstitial="false">14%가 6월 분기 실적을 발표</a>했으며, 더 넓은 지수를 구성하는 기업들의 혼합 실적 성장률은 여전히 ​​양호하다. 이번 주에는 기술 보고 시즌이 공식적으로 시작될 것이며, 이는 최근 주에 가파른 하락세를 보인 시장의 향방을 잠재적으로 결정할 수 있다.
지난주 주요 사건: 기술주의 실적 시즌은 지난주 칩 장비 제조업체 ASML 홀딩 N.V.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>)의 실적 발표로 와만하게 시작되었다. 이 회사의 주가는 약한 3분기 전망과 중국 칩 금지를 둘러싼 지정학적 우려로 인해 약 16% 하락했다. 넷플릭스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>)의 지침은 투자자들을 실망시켰지만 증권사 측 분석가들이 결과에 열광하면서 주가는 크게 하락하지 않았다.
투자자들은 뱅크 오브 아메리카(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>), 모건 스탠리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) 및 골드만삭스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) 등 나머지 대형 은행들의 실적 보고서에 환호했다. 투자 은행 사업의 반등과 강력한 트레이딩 매출이 은행들의 매출을 강화하는 데 도움이 되었다.
팩트셋(FactSet)의 최신 실적 전망 조사 <a href="https://advantage.factset.com/hubfs/Website/Resources%20Section/Research%20Desk/Earnings%20Insight/EarningsInsight_071924.pdf">보고서</a>에 따르면 이들 기업 중 80%가 예상보다 높은 주당 이익을 보고했는데, 이는 5년 평균인 77%와 비교된다. 평균 상승 여력은 약 5.5%이지만, 이는 5년 평균 상승률 8.6%보다 낮다.
관련 정보: <a href="https://www.benzinga.com/money/best-tech-stocks">지금 가장 핫한 기술주</a>
실적 트렌드: 팩트셋에 따르면 S&amp;P 500 기업들의 2분기 혼합 실적 증가율은 현재 9.7%로 전주의 9.1%보다 높아진 것으로 추정된다. 이 추정치가 달성되면 분기 실제 성장률은 2021년 4분기 이후 보고된 전년 동기 대비 가장 높은 성장률을 기록할 것이라고 덧붙였다. 2분기 역시 4분기 연속 성장을 기록할 것으로 보인다.
S&amp;P 500 11개 부문 중 8개 부문이 전년 동기 대비 실적 성장을 기록할 것으로 예상되며, 그 중 통신 서비스, 의료, IT, 금융 부문 4개 부문이 두 자릿수 실적 성장을 기록할 가능성이 높다. 반면, 소재 업종을 중심으로 3개 업종의 실적 감소가 예상된다.
이번 주의 이슈: 이번 주에는 다우 30 지수 구성요소 7개를 포함해 S&amp;P 500 기업 138개 기업들의 실적 보고서가 나올 것이라고 팩트셋의 보고서가 밝혔다. 이번 주의 실적 발표 목록에는 통신, 자동차, 철강, 칩, 주택 건설, 방위, 항공 및 기술 산업의 기업들이 포함된다.
테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)와 알파벳(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)은 S&amp;P 500과 나스닥 지수에서 높은 비중을 차지하고 있어 주목받는 기업들 중 하나이다. 테슬라는 전년 동기 대비 주당 순이익이 91센트에서 62센트로 급격히 감소할 것으로 예상되는 반면, 매출은 훨씬 완만하게 0.80% 감소한 247억 3천만 달러를 기록했을 수 있다. 이 이익성에 더 큰 영향을 미치는 것은 일론 머스크의 회사가 어려운 수요 환경에서 생산량을 늘리기 위해 의존해 온 가격 인하에서 비롯된다.
<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39810457/as-tesla-stock-bounces-back-fund-manager-says-elon-musk-led-company-offers-good-set">분석가들과 펀드 매니저들은</a> 회사가 해당 분기에 양호한 납품 실적을 보고한 후 낙관적이다. 하반기에도 반전이 있을 것으로 예상된다.
알파벳의 실적은 AI를 활용한 거대 기업들 중 최초로 분기별 실적을 발표하는 기업이기 때문에 중요하며, 이는 나머지 기업들의 실적 속도를 정할 수 있다.
지난주 주요 지수가 사상 최고치에서 후퇴하면서 주식시장이 큰 타격을 입었다. Benzinga Pro 데이터에 따르면 나스닥 100 지수의 성과를 추적하는 지수인 Invesco QQQ Trust(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)는 금요일 0.89% 하락한 475.24달러에 마감했다. 이 ETF는 7월 10일에 도달한 502.96달러의 사상 최고치보다 낮게 거래되고 있다. SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)도 금요일 0.66% 하락한 548.99달러로 마감했다.
이번 주 주목할 만한 실적 발표 기업은 다음과 같다:
월요일
개장 전:
<ul>
<li>버라이즌 커뮤니케이션스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>)</li>
</ul>
장 마감 후:
<ul>
<li>애질리시스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGYS#NASDAQ">AGYS</a>)</li>
<li>클리블랜드 클리프스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>)</li>
<li>뉴코 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>)</li>
<li>NXP 반도체 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>)</li>
</ul>
화요일
개장 전:
<ul>
<li>코카콜라 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>)</li>
<li>프리포트 맥모란 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>)</li>
<li>GATX 코퍼레이션 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GATX#NYSE">GATX</a>)</li>
<li>GE 에어로스페이스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>)</li>
<li>제너럴 모터스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>)</li>
<li>킴벌리 클라크 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>)</li>
<li>록히드 마틴 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>)</li>
<li>필립 모리스 인터내셔널 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>)</li>
<li>풀트그룹 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHM#NYSE">PHM</a>)</li>
<li>퀘스트 다이아그노스틱스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>)</li>
<li>스포티파이 테크놀로지 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>)</li>
<li>UPS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>)</li>
</ul>
장 마감 후:
<ul>
<li>알파벳</li>
<li>캐피털 원 파이낸셜 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>)</li>
<li>처브 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>)</li>
<li>마텔 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAT#NASDAQ">MAT</a>)</li>
<li>패키징 코퍼레이션 오브 아메리카 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKG#NYSE">PKG</a>)</li>
<li>씨게이트 테크놀로지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>)</li>
<li>테슬라</li>
<li>텍사스 인스트루먼트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>)</li>
<li>비자 .(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>)</li>
</ul>
수요일
개장 전:
<ul>
<li>AT&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>)</li>
<li>체크포인트 소프트웨어 테크놀로지스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHKP#NASDAQ">CHKP</a>)</li>
<li>보스톤 사이언티픽 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>)</li>
<li>CME 그룹 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>)</li>
<li>제너럴 다이내믹스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>)</li>
<li>올드 도미니언 프레이트 라인 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>)</li>
<li>GE 베르노바 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>)</li>
<li>써모 피셔 사이언티픽 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>)</li>
</ul>
장 마감 후:
<ul>
<li>치폴레 멕시칸 그릴 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>)</li>
<li>에드워드 라이프사이언스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>)</li>
<li>포드 자동차 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>)</li>
<li>IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>)</li>
<li>나이트 스위프트 트랜스포테이션 홀딩스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNX#NYSE">KNX</a>)</li>
<li>라스베가스 샌즈 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>)</li>
<li>메리티지 홈즈 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTH#NYSE">MTH</a>)</li>
<li>월풀 코퍼레이션 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHR#NYSE">WHR</a>)</li>
<li>서비스나우 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) ORLY</li>
<li>오릴리 오토모티브 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>)</li>
</ul>
목요일
개장 전:
<ul>
<li>애브비 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</li>
<li>아메리칸 항공 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>)</li>
<li>아스트라제네카 PLC(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>)</li>
<li>컴캐스트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>)</li>
<li>다우 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>)</li>
<li>해즈브로 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAS#NASDAQ">HAS</a>)</li>
<li>허니웰 인터내셔널 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>)</li>
<li>사노피 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>)</li>
<li>사우스웨스트 항공 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>)</li>
<li>ST마이크로일렉트로닉스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>)</li>
<li>유니언 퍼시픽 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>)</li>
<li>제록스 홀딩스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRX#NASDAQ">XRX</a>)</li>
</ul>
장 마감 후:
<ul>
<li>스카이웨스트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYW#NASDAQ">SKYW</a>)</li>
<li>주니퍼 네트웍스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNPR#NYSE">JNPR</a>)</li>
<li>데커스 아웃도어 코퍼레이션 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>)</li>
<li>보이드 게이밍 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>)</li>
<li>BJ 레스토랑 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJRI#NASDAQ">BJRI</a>)</li>
<li>베리사인 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSN#NASDAQ">VRSN</a>)</li>
</ul>
금요일
개장 전:
<ul>
<li>3M 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>)</li>
<li>반즈 그룹 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/B#NYSE">B</a>)</li>
<li>브리스톨-마이어스 스퀴브 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</li>
<li>뉴웰 브랜즈 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>)</li>
<li>콜게이트 파몰리브 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>)</li>
<li>차터 커뮤니케이션즈 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>)</li>
</ul>
차기 기사:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/39857569/american-express-q2-earnings-ceo-raises-annual-profit-and-marketing-spend-outlook-after-q2-profit-b">아메리칸 익스프레스, 2분기 실적: CEO의 2분기 순이익 안정화에 대한 전망</a></li>
</ul>
Photo: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

AbbVie

뉴스

에 대한 최신 뉴스 AbbVie (NYSE:ABBV) 주식

목요일, 1월 30, 2025

일요일, 1월 19, 2025

토요일, 1월 04, 2025

화요일, 12월 24, 2024

월요일, 12월 23, 2024

일요일, 11월 17, 2024

금요일, 11월 15, 2024

일요일, 7월 21, 2024

일요일, 7월 07, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌